Intensity Therapeutics Reports Promising Early Efficacy Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab in Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium®
Spoke,
In a Highly Refractory Population the Disease Control Rate (DCR), at the First Radiologic Assessment, was 57% Median Overall…